Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 6/20 | 0.47 |
| ▸ | GRK2 | P25098 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3202432 | 0.76 | MAPT (0.51) | SMN1; SMN2POLBGRK2TDP1MAPT | |
| SCHEMBL3116490 | 0.75 | TSHR (0.44) | SMN1; SMN2MAPK1POLBGRK2TDP1 | |
| SCHEMBL19334308 | 0.74 | SMN1; SMN2 (0.68) | SMN1; SMN2MAPK1TDP1MAPTCYP3A4 | |
| SCHEMBL6701011 | 0.73 | ALDH1A1 (0.40) | CYP3A4LMNA | |
| SCHEMBL4012060 | 0.72 | CYP3A4 (0.55) | SMN1; SMN2POLBGRK2TDP1MAPT | |
| SCHEMBL13272204 | 0.71 | ALDH1A1 (0.64) | SMN1; SMN2MAPK1MAPTKMT2ATP53 | |
| SCHEMBL2634202 | 0.71 | TSHR (0.48) | SMN1; SMN2MAPK1MAPTRAB9ATHRB | |
| SCHEMBL10536306 | 0.70 | TSHR (0.47) | SMN1; SMN2MAPK1MAPTRAB9ATHRB | |
| SCHEMBL10536301 | 0.70 | TSHR (0.47) | SMN1; SMN2MAPK1MAPTRAB9ATHRB | |
| SCHEMBL10536613 | 0.70 | TSHR (0.47) | SMN1; SMN2MAPK1MAPTRAB9ATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142979-A1 | Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors | PHARMACIA CORPORATION | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142979-A1 | Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors | MMP3, MMP13, MMP10 | SMN1; SMN2 2960/4885MAPK1 3255/4885POLB 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.